Plasma homocysteine (Hcy) and APOE ε4 are associated with the risk of NDs, especially in patients with AD and MCI, with patients with non-carrier genotypes showing more pronounced changes in the neurodegenerative marker (phosphorylated tau 217) (Lin et al., 2025). Here, MAPT is linked to Alzheimer disease.